Warp 10 Used By NASA & The Military For Pain Relief.

The term "minor pain" is rapidly becoming an oxymoron as our aging population becomes more prone to arthritis and the muscle and joint pain that accompany the aging process. The American Pain Society estimates that 45% of the population seeks medical help for persistent pain at sometime in their lives. Medical economists' estimate that pain costs the U.S. some $100 billion every year, including 515 million workdays lost and 40 million doctor visits.1

Quantum Devices, believe they have a better answer for the economic and personal distress of NSAIDS for the temporary relief of persistent minor pain. The WARP 10® is designed to assist armed forces personnel on the front lines with immediate first aid and care for minor injuries and pain, thereby improving endurance in combat. The WARP 10 was originally developed under a contract for the Defense Advanced Research Projects Agency (DARPA), by QDI, the pioneers of the NASA , High Emissivity Aluminiferous Light-emitting Substrate, HEALS® technology.

QDI invented the high-intensity, solid-state lighting systems for NASA  that have become the gold standards for photobiomodulation (PBMT) research, photo dynamic cancer therapy and agriculture research. The WARP 10 is a high intensity, hand-held, portable, LED (light emitting diode) unit, intended for the treatment of chronic pain by emitting energy in the near-infrared (NIR) spectrum. This includes: the temporary relief of minor muscle and joint pain, arthritis and muscle spasms; and relieving stiffness, promoting relaxation of muscle tissue and temporarily increasing local blood circulation, where applied.

QDI is dedicated to the principle that light provides the power for all life on earth. We believe the quality, delivery and control of light is essential to the wellness of the human race and our advancement into the future. To this end we are pleased to offer the FDA approved consumer version of the WARP 10 as a viable alternative to the cost and complications associated with the overuse of NSAIDS for persistent minor pain relief.
Arthritis is the second most common reason for purchasing non-prescription (over-the-counter, NSAIDs) drugs.1 Adverse events associated with the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs - such as ibuprofen, aspirin, acetominophen) are reported more frequently to the Food and Drug Administration than are those associated with any other group of drugs.3 Conservative calculations for the United States estimate that approximately 107,000 patients are hospitalized annually for NSAID-related GI complications and at least 16,500 NSAID-related deaths occur each year among arthritis patients alone (more than asthma, cervical cancer or melanoma combined). 2,4,5


SOURCES
1) Canadian Arthritis Society
2) Centers for Disease Control and Prevention
3) Loeb DS, Ahlquist DA, Talley NH, Mayo Clinical Procedure, 1992 Apr;67(4):354-64
4) Business Week, Feb. 16, 1998, p. 71-72
5) Singh, Gurkirpal, "Recent Considerations in Nonsteroidal Anti-Inflammatory Drug Gastropathy", American Journal of Medicine, pp. 31S-38S, Volume 105 (iB), July 27, 1998